4-Hydroxybenzamide CAS:619-57-8

4-Hydroxybenzamide

Chemical Name:4-Hydroxybenzamide
CAS.NO:619-57-8
Synonyms:4-Hydroxybenzamide
Benzamide,4-hydroxy
4-hydroxy-benzamide
4-hydroxyphenylformamide
4-Hydroxy-benzoesaeure-amid
para-hydroxybenzamide
P-HYDROXYBENZAMIDE
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 345.3±25.0 °C at 760 mmHg
Melting Point 161-162 °C(lit.)
Molecular Formula C7H7NO2
Molecular Weight 137.136
Flash Point 162.6±23.2 °C
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Febuxostat(CAS:144060-53-7).



We are professional 4-Hydroxybenzamide manufacturer and P-HYDROXYBENZAMIDE supplier in China, We offer quality 4-hydroxy-benzamide you can fully trust, also we have India factory and producer of 4-Hydroxybenzamide,Pls send inquiry of P-HYDROXYBENZAMIDE CAS:619-57-8 to info@nbinno.com if you have any interests, thank you!


Related News: Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.Isocianato de 4-cloro-3- (trifluorometil) fenilo CAS:327-78-6 Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.3-(Methylthio)butanal CAS:16630-52-7 DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.2,4-Dichloropyrimidine CAS:3934-20-1 The glucagon-only configuration may be helpful in rare conditions that often lead to chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI).Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.